Nomura Holdings Inc. Purchases New Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Nomura Holdings Inc. purchased a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 53,200 shares of the company's stock, valued at approximately $641,000. Nomura Holdings Inc. owned approximately 0.17% of Delcath Systems at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Vivo Capital LLC raised its holdings in Delcath Systems by 71.4% during the fourth quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after purchasing an additional 711,574 shares in the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Delcath Systems during the 4th quarter valued at $7,371,000. Millennium Management LLC raised its stake in shares of Delcath Systems by 53.4% in the 4th quarter. Millennium Management LLC now owns 314,675 shares of the company's stock worth $3,789,000 after buying an additional 109,568 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Delcath Systems by 14.7% in the 4th quarter. Geode Capital Management LLC now owns 288,951 shares of the company's stock worth $3,481,000 after buying an additional 37,056 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its holdings in shares of Delcath Systems by 89.6% in the fourth quarter. Kennedy Capital Management LLC now owns 258,782 shares of the company's stock valued at $3,116,000 after buying an additional 122,318 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DCTH shares. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price (up from $24.00) on shares of Delcath Systems in a report on Friday. Wall Street Zen raised shares of Delcath Systems from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Price Performance

Shares of DCTH traded down $0.04 during trading hours on Monday, hitting $16.11. 551,896 shares of the company were exchanged, compared to its average volume of 372,067. The company has a market capitalization of $561.05 million, a PE ratio of -11.93 and a beta of 0.72. The firm has a fifty day simple moving average of $13.05 and a 200-day simple moving average of $12.99. Delcath Systems, Inc. has a one year low of $6.33 and a one year high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). The company had revenue of $19.80 million for the quarter, compared to analysts' expectations of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. Sell-side analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.